<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00534027</url>
  </required_header>
  <id_info>
    <org_study_id>20060295</org_study_id>
    <nct_id>NCT00534027</nct_id>
  </id_info>
  <brief_title>A Phase 1b/2 Study of AMG 655 in Combination With Paclitaxel and Carboplatin for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer</brief_title>
  <official_title>A Phase 1b/2 Study of AMG 655 in Combination With Paclitaxel and Carboplatin for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <brief_summary>
    <textblock>
      Part 1 is complete. Part 2 is a multi-center, randomized, double-blind, placebo-controlled,&#xD;
      phase 2 segment that will commence upon identification of the maximum tolerated dose in part&#xD;
      1. The Primary objective of Part 2 of the study is to estimate efficacy in combination with&#xD;
      carboplatin and paclitaxel. Subjects will be randomized at a 1:1:1 ratio to 1 of 3 treatment&#xD;
      arms. Subjects in each of the 3 arms will receive up to 6 cycles of paclitaxel/carboplatin&#xD;
      (at the same dose and schedule in part 1) in combination with either AMG 655 at the maximum&#xD;
      tolerated dose (Arm 1), AMG 655 at a lower dose (Arm 2), or AMG 655 placebo (Arm 3) IV Q3W.&#xD;
      Randomization will be stratified by ECOG (0 or 1) and disease stage (IIIb or IV/recurrent).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>Until disease progression</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate, duration of response, time to response, overall survival and incidence of adverse events and clinical laboratory abnormalities</measure>
    <time_frame>Until disease progression</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">172</enrollment>
  <condition>Non-Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low Dose AMG 655 with paclitaxel/carboplatin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo with paclitaxel/carboplatin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AMG 655 High doseplus paclitaxel/carboplatin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMG 655</intervention_name>
    <description>AMG 655 is a monoclonal antibody directed against TR-2.</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>AMG 655 placebo</intervention_name>
    <description>Inactive dummy AMG 655 (to maintain blind)</description>
    <arm_group_label>Arm 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Disease Related&#xD;
&#xD;
               -  Histologically or cytologically confirmed non-small cell lung cancer.&#xD;
&#xD;
               -  Subjects must have advanced non-small cell lung cancer defined as stage IIIB with&#xD;
                  malignant pleural effusion or stage IV or recurrent disease.&#xD;
&#xD;
               -  Planning to receive up to 6 cycles of chemotherapy&#xD;
&#xD;
               -  Eastern Cooperative Oncology Group (ECOG) score of 0 or 1 Demographic&#xD;
&#xD;
               -  Men or women &gt; 18 years of age Ethical&#xD;
&#xD;
               -  Adequate Hematological, renal, hepatic and coagulation function General&#xD;
&#xD;
               -  Plan to begin protocol specific therapy &lt; 7 days after enrollment/randomization&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Disease Related&#xD;
&#xD;
               -  Untreated or symptomatic central nervous system metastases. Subjects with a&#xD;
                  history of brain metastases are eligible if definitive therapy has been&#xD;
                  administered (surgery and/or radiation therapy), there is no planned treatment&#xD;
                  for brain metastasis and the subject is clinically stable and off corticosteroids&#xD;
                  for at least 14 days before enrollment/randomization.&#xD;
&#xD;
               -  Prior chemotherapy as follows:&#xD;
&#xD;
               -  Any prior chemotherapy for advanced non-small cell lung cancer&#xD;
&#xD;
               -  Any prior adjuvant chemotherapy for non-small cell lung cancer &lt; 52 weeks prior&#xD;
                  to enrollment/randomization. Adjuvant chemotherapy completed &gt; 52 weeks prior to&#xD;
                  randomization is permitted.&#xD;
&#xD;
               -  Any prior chemoradiation.&#xD;
&#xD;
               -  Central (chest) radiation therapy &lt; 28 days prior to randomization, radiation&#xD;
                  therapy for peripheral lesions &lt; 14 days prior to enrollment/randomization&#xD;
&#xD;
               -  Other abnormal medical conditions&#xD;
&#xD;
               -  Documented myocardial infarction or unstable/uncontrolled cardiac condition&#xD;
&#xD;
               -  History of arterial thrombosis, pulmonary embolus, deep vein thrombosis or&#xD;
                  hemorrhagic disorders&#xD;
&#xD;
               -  Major surgical procedure &lt; 30 days prior to enrollment/randomization or not yet&#xD;
                  recovered from prior major surgery, Minor surgical procedure &lt; 7 days prior to&#xD;
                  enrollment/randomization or not yet recovered from prior minor surgery&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <removed_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Czech Republic</country>
    <country>France</country>
    <country>Hungary</country>
    <country>Poland</country>
    <country>Spain</country>
  </removed_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>December 2015</verification_date>
  <study_first_submitted>September 20, 2007</study_first_submitted>
  <study_first_submitted_qc>September 20, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 24, 2007</study_first_posted>
  <disposition_first_submitted>December 14, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>December 14, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">January 14, 2016</disposition_first_posted>
  <last_update_submitted>December 14, 2015</last_update_submitted>
  <last_update_submitted_qc>December 14, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NSCLC</keyword>
  <keyword>Non-Small Cell Lung Cancer</keyword>
  <keyword>Paclitaxel</keyword>
  <keyword>Carboplatin</keyword>
  <keyword>AMG 655</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Conatumumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

